MammaTyper molecular diagnostic test for breast cancer patients now available in Euro

[News]

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies and its subsidiary BioNTech Diagnostics GmbH, today announced the launch of MammaTyper, a CE-IVD marked molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue, for universal use in pathology laboratories.

More... (http://www.news-medical.net/news/20150611/MammaTyper-molecular-diagnostic-test-for-breast-cancer-patients-now-available-in-Europe.aspx)